|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-7-20
|
|
pubmed:abstractText |
The so-called thorough QT/QTc (TQT) studies required for every new pharmaceutical compound are negative if upper single-sided 95% confidence interval (CI) of placebo and baseline corrected QTc prolongation is <10 ms. This tight requirement has many methodological implications. If the investigated drug has a fast action and ECGs cannot be obtained at stable heart rates, QT/RR hysteresis correction is needed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1542-474X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
242-50
|
|
pubmed:meshHeading |
pubmed-meshheading:19614635-Adult,
pubmed-meshheading:19614635-Contrast Media,
pubmed-meshheading:19614635-Cross-Over Studies,
pubmed-meshheading:19614635-Double-Blind Method,
pubmed-meshheading:19614635-Electrocardiography,
pubmed-meshheading:19614635-Exercise Test,
pubmed-meshheading:19614635-Female,
pubmed-meshheading:19614635-Heart Conduction System,
pubmed-meshheading:19614635-Heart Rate,
pubmed-meshheading:19614635-Humans,
pubmed-meshheading:19614635-Male,
pubmed-meshheading:19614635-Middle Aged,
pubmed-meshheading:19614635-Models, Cardiovascular,
pubmed-meshheading:19614635-Organometallic Compounds,
pubmed-meshheading:19614635-Placebos
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Correction for QT/RR hysteresis in the assessment of drug-induced QTc changes--cardiac safety of gadobutrol.
|
|
pubmed:affiliation |
St. Paul's Cardiac Electrophysiology, London, England. marek.malik@btinternet.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
